There is accumulating evidence that platelets play roles beyond their traditional functions in
thrombosis and hemostasis, eg, in inflammatory processes, infection and cancer, and that …

Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder
characterized by decreased platelet counts and an increased risk of bleeding. Multiple …

Background Immune thrombocytopenia (ITP) is an autoimmune disease characterized by
autoantibody-mediated platelet destruction. Treatment with CM313, a novel anti-CD38 …

Currently approved immune checkpoint inhibitor therapies targeting the PD-1 and CTLA-4
receptor pathways are powerful treatment options for certain cancers; however, most …

Platelets have long been recognized as key players in hemostasis and thrombosis;
however, growing evidence suggests that they are also significantly involved in cancer, the …

Immune thrombocytopenia (ITP) is a rare autoimmune disease due to an abnormal T cell
response, notably supported by splenic T follicular helper cells, that stimulates the …

Platelets are small anucleate blood cells generated from megakaryocytes in the bone
marrow and cleared in the reticuloendothelial system. At the site of vascular injury, platelet …

Immune thrombocytopenia (ITP) is an autoimmune disease defined by low platelet counts
which presents with an increased bleeding risk. Several genetic risk factors (eg …

Hundreds of billions of platelets are cleared daily from circulation via efficient and highly
regulated mechanisms. These mechanisms may be stimulated by exogenous reagents or …

Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder,
characterized by a low platelet count (< 100× 109/L) in the absence of other causes …